Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Heidi J SilverDianna OlsonDustin MayfieldPatricia WrightHui NianMona MashayekhiJohn R KoetheKevin D NiswenderJames M LutherNancy J BrownPublished in: Diabetes, obesity & metabolism (2023)
Although both liraglutide and CR are valuable strategies for cardiometabolic risk reduction, CR was associated with greater weight loss and more favourable improvements in body composition than treatment with liraglutide alone. Differences in the response to each of these interventions enables patients to be stratified to the most optimal intervention for their personal risk factors.
Keyphrases
- weight loss
- body composition
- risk factors
- end stage renal disease
- bariatric surgery
- resistance training
- chronic kidney disease
- bone mineral density
- ejection fraction
- newly diagnosed
- roux en y gastric bypass
- gastric bypass
- type diabetes
- metabolic syndrome
- physical activity
- peritoneal dialysis
- prognostic factors
- weight gain
- body mass index
- patient reported outcomes
- smoking cessation
- high intensity
- skeletal muscle